A wave of analyst downgrades is punishing The Trade Desk after a disastrous earnings report, underscoring the market's brutal response to missed guidance. Elsewhere, positive FDA approvals are providing a much-needed lift for biotech, while traders brace for the July jobs report to dictate the Fed's next step.
The Trade Desk (TTD) is down over 22% pre-market after a disastrous Q2 report and a wave of subsequent analyst downgrades. The company reported revenue of $715.1M vs. $751.4M expected and guided Q3 revenue to just $650M, far below prior estimates. The report validated bear concerns about growth deceleration and margin compression, prompting downgrades to Neutral/Underperform from Baird, Guggenheim, and Raymond James, with Baird slashing its price target to $9 from $27.
Why it matters
This is a high-conviction short setup. The combination of a significant top-and-bottom-line miss, a major guidance cut, and a unified chorus of tier-1 downgrades signals a fundamental story breakdown. The stock was already down 80% from its highs, and this news confirms the business deterioration is accelerating, likely leading to further downside as the market reprices its growth trajectory.
Life Insurance Corporation of India (LIC) shares gained nearly 2% on Friday, extending recent gains after reporting a record 730 basis point expansion in its Value of New Business (VNB) margin to 22.9% for Q1FY27, crushing analyst estimates. The strong performance prompted a wave of analyst upgrades from firms including Motilal Oswal, Jefferies, and Macquarie, who reiterated 'Buy' ratings and raised price targets.
Why it matters
This is a classic episodic pivot setup. A significant earnings surprise, particularly the record VNB margin, signals a fundamental story change. The move is amplified by a raft of bullish analyst actions, serving as a powerful catalyst for a potential breakout from its multi-month base. For traders, this combination of fundamental surprise and Wall Street validation provides a strong long-side thesis.
The brutal punishment of software stocks on weak guidance that we've been tracking extended through Thursday. High-multiple names cratered on any sign of weakness, with AppLovin (APP) and HubSpot (HUBS) expanding the pre-market plunges we noted yesterday to close down 19% and 24%, respectively. They were joined by Datadog (DDOG), which fell 14% on guidance concerns, even with some reporting strong revenue growth. Memory chip names like Western Digital (WDC) and SanDisk (SNDK) also fell sharply despite some beats, highlighting intense market scrutiny.
Why it matters
This highlights a significant shift in market sentiment where strong headline numbers are no longer sufficient. Guidance and margins are paramount, and any disappointment is being severely punished. This creates a target-rich environment for short-side gapper fades, as high-multiple stocks are de-rating quickly on negative news. The weakness in memory chips also signals that concerns about the HBM supply/demand balance are beginning to weigh on the sector.
Kodiak Gas Services (KGS) reported record Q2 financial results, with adjusted EBITDA up 21.7% year-over-year. Citing strong demand for its compression services and progress in its new Power Infrastructure segment, the company raised its full-year 2026 guidance for both Adjusted EBITDA and discretionary cash flow.
Why it matters
A strong earnings beat combined with a guidance raise is a classic long setup. Kodiak's results point to robust operational performance and successful expansion into the high-demand power infrastructure sector. This provides a clear fundamental catalyst that could drive a post-earnings gap and continuation move.
The FDA has granted accelerated approval to Replimune's (REPL) drug Tudriqev for a difficult-to-treat form of advanced skin cancer. This marks the company's first marketed product and comes after multiple previous regulatory setbacks. The approval, granted for use in combination with Bristol Myers Squibb's Opdivo, was reconsidered after a push from physicians and patient advocates.
Why it matters
This is a major binary event win for Replimune, providing its first commercial product and a significant potential revenue stream. The approval de-risks the company's lead asset and validates its platform, creating a clear catalyst for a stock re-rating. Traders will watch for details on the launch and commercial uptake, which will be critical for sustaining momentum. Note, however, the label specifies a lower response rate (24.2%) than the company had previously cited (33.6%), which could temper long-term expectations.
Following up on the pending regulatory decision we tracked yesterday, Moderna (MRNA) announced on Thursday that the US FDA has officially approved mFlusiva, the first mRNA-based seasonal influenza vaccine approved in the U.S. The approval is for use in adults aged 50 and older and follows a unanimous recommendation from the FDA's advisory committee.
Why it matters
This approval marks a significant regulatory win for Moderna, opening up a new, large commercial market beyond its COVID-19 products. It provides a new revenue stream and further validates the company's mRNA platform technology for indications outside of the pandemic. This catalyst de-risks the product's commercialization and strengthens the company's long-term growth narrative.
Clinical-stage drug developer Braveheart Bio Inc. (BRVE) surged 68% in its Nasdaq debut on Thursday, capping a $382.5 million IPO. The company, which was founded in 2024 to develop treatments for hypertrophic cardiomyopathy, has attracted significant backing from top-tier investors including a16z's biotech fund and Patient Square Capital.
Why it matters
A successful biotech IPO with a strong debut pop indicates robust investor appetite for new, high-science stories, particularly in specialized disease areas. For traders, a hot IPO like this creates a new high-volatility name to watch for follow-through momentum or potential parabolic exhaustion setups in the coming days and weeks. The strong institutional backing adds a layer of credibility.
Shares of Insmed Inc. (INSM) surged 31.8% on Thursday on extremely high volume. While the company has not issued a specific press release, such a significant move in a biotech stock typically indicates a major positive development, such as strong late-stage clinical trial data, a regulatory breakthrough, or M&A speculation.
Why it matters
A massive, unexplained single-day move like this signals a fundamental re-rating by informed market participants. This is a powerful catalyst-driven event, creating a new high-momentum name to watch. Traders will be looking for confirmation of the news driver and for signs of either continuation or exhaustion in the coming sessions. The lack of an official announcement adds to the intrigue and potential volatility.
Block (SQ) reported strong Q2 results on Wednesday, beating Wall Street estimates as gross profit surged 25% year-over-year. The company raised its full-year guidance for all key metrics. A key highlight was the Square unit, which showed its strongest gross payment volume growth in three years, signaling accelerating momentum in its core merchant business.
Why it matters
Block's results indicate a significant positive fundamental inflection. The acceleration in the core Square business, combined with a full-year guidance lift, constitutes a genuine episodic pivot. This suggests the company's growth story is re-accelerating, making it a compelling candidate for long-side continuation trades.
Mizuho downgraded Six Flags (FUN) to 'Underperform' from 'Outperform' and slashed its price target to $10.00 from $28.00. The downgrade is based on what the firm calls poor communication and misrepresentation of attendance figures, where management allegedly understated the impact of asset sales on visitor numbers. Mizuho expects Street EBITDA estimates to fall and sees limited growth prospects.
Why it matters
A dramatic downgrade like this from a tier-1 desk, which questions management's credibility, is a powerful bearish catalyst. It provides a clear short thesis for a stock that is already down 37% over the past year. Traders can expect this to trigger further selling pressure as other analysts are likely to re-evaluate their models in light of Mizuho's findings.
U.S. stock futures are mixed heading into Friday's open as traders brace for the July jobs report. Dow futures are slipping, while the S&P 500 and Nasdaq 100 are pointing to a higher open. Overnight, the S&P 500 (ES) saw sellers push the market down from recent highs, but key support levels are holding. The 7700 level on the S&P has emerged as a key options-related battleground.
Why it matters
The market is in a holding pattern ahead of a major macro catalyst. The tactical levels on the major indices (SPY, QQQ) and the dealer positioning around key options strikes will be critical for framing intraday trades once the NFP number is released. A break of established support or resistance levels on volume post-report will likely dictate the day's trend.
With indices pulling back from recent highs, all eyes are on today's July Nonfarm Payrolls (NFP) report. Consensus expects a headline print of +80,000 jobs, up from 57,000 in June, with the unemployment rate holding at 4.2%. Softer leading indicators like ADP and ISM services employment have biased market expectations toward a weaker number.
Why it matters
This is the key macro catalyst for the session. The NFP print is seen as a critical data point that will heavily influence the Fed's September rate hike decision. A 'Goldilocks' number around consensus may be absorbed, but a significant upside surprise could reignite inflation fears, spike yields, and pressure risk assets. Conversely, a major miss could signal a hard landing is becoming more likely. Straddle pricing suggests the market isn't braced for a huge move, creating a potential volatility opportunity.
Biotech Catalysts Deliver Binary Outcomes A string of FDA approvals and key trial updates are creating significant, catalyst-driven moves in the biotech sector. Replimune finally secured approval for its skin cancer drug after prior setbacks, Moderna's new flu vaccine was greenlit, and Ocugen received FDA clearance for a key Phase 3 trial. Conversely, Zymeworks signaled financial distress by pulling its cash runway guidance.
Earnings Reports Create Sharp Divergences The market is punishing earnings misses and guidance shortfalls with extreme prejudice. The Trade Desk plunged over 20% on a major miss and weak outlook, joined by Performance Food Group. In contrast, companies with strong results and guidance like LIC, Block, and Kodiak Gas Services were rewarded, highlighting a brutal bifurcation in post-earnings reactions.
Analyst Actions Serve as Major Catalysts Tier-1 analyst calls are driving significant price action. A wave of downgrades from Baird, Guggenheim, and Raymond James accelerated The Trade Desk's collapse. Conversely, a 'Buy' initiation from Jefferies sent Kalyan Jewellers up 5%, and multiple upgrades on LIC fueled its breakout after a strong report. A major downgrade from Mizuho on Six Flags is setting up a potential short trade.
Focus Shifts to July Jobs Report With earnings season winding down, market focus has shifted to today's July jobs report. Consensus expects a headline print of +80k. The report is viewed as a critical input for the Fed's September rate decision, with a surprisingly strong number likely to increase hike probabilities and pressure risk assets.
Capital Rotation Continues as Dow Hits New Highs The Dow Jones Industrial Average crossed 54,000 for the first time, signaling a significant rotation of capital from mega-cap tech into more traditional blue-chip names. While the broader market shows strength, with equal-weight indices confirming the move, leadership is clearly shifting away from the concentrated semiconductor and AI plays that dominated earlier this year.
What to Expect
2026-08-07—US July Jobs Report (Nonfarm Payrolls) is released.
2026-08-12—US Consumer Price Index (CPI) for July is released.
2026-09-15—Next FOMC meeting begins, with prediction markets split on a potential rate hike.
2026-09-16—FOMC releases its interest rate decision and economic projections.
2026-09-30—PDUFA date for Lantheus' MK-6240 for tau PET imaging in Alzheimer's disease.
How We Built This Briefing
Every story, researched.
Every story verified across multiple sources before publication.
🔍
Scanned
Across multiple search engines and news databases
617
📖
Read in full
Every article opened, read, and evaluated
170
⭐
Published today
Ranked by importance and verified across sources
12
— The Tape Reader
🎙 Listen as a podcast
Subscribe in your favorite podcast app to get each new briefing delivered automatically as audio.
Apple Podcasts
Library tab → ••• menu → Follow a Show by URL → paste